" After further discussion, as an omega-3 expert, she opined that it is highly likely that the R-I trial with pure EPA will succeed (despite her losing her job due to the AMRN patent victory). She stated that the high purity and high dose (4 gram) of V were key for efficacy in her view.
Thought you were taking my opinion on the subject...":>)
Good story...The case for EPA (in 4 gm/doses..((invest))..Is very compelling because the evidence at the cellular level lines up with the clinical effects..
Once R-I results are in it will not take the medical profession very long to "GET IT"..Doctors I talk to are very impressed...
VuBru, One question that comes to mind is if BP knows that AMRN has a strong patent position and that Pure EPA at the right dose works, does it not follow that they would consider AMRN to be a takeover candidate? My point being that if this view is shared across BP then AMRN has set itself in a very good position. Most Interesting. Thanks for sharing your story.
That's encouraging but based on the pps, that view doesn't seem to be shared amongst the medical and bp community otherwise it would be much higher....however it certainly works for me!